Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies
Multiple Myeloma
Hodgkin's Lymphoma
Cutaneous T Cell Lymphoma

Interventions

DRUG: Tinostamustine

Sponsor

Mundipharma Research Limited